News
Takeda findings may minimise haemophilia treatment side effects
Immune responses against factor VIII (FVIII) – used to treat haemophilia A – are influenced by the microenvironment of antigen presenting cells.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Immune responses against factor VIII (FVIII) – used to treat haemophilia A – are influenced by the microenvironment of antigen presenting cells.